Rivaroxaban Tablet, Film Coated
Product Images NDC 14445-147

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Rivaroxaban (NDC 14445-147). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Indoco Remedies Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure-04 (Figure 04)

This text appears to be a table comparing the number of subjects at risk over days from randomization for Rivaroxaban and Warfarin. It shows the progression of subjects over time for each treatment group. The table lists the number of subjects at risk for both Rivaroxaban and Warfarin at different time points.*

FDA Label Image

Figure-05 (Figure 05)

FDA Label Image

Figure-08 (Figure 08)

Not available.*

FDA Label Image

Figure-10 (Figure 10)

This text seems to contain data related to a clinical trial involving Rivaroxaban and a placebo. The data includes the incidence rates over time, with the number of subjects at risk for each treatment group at different intervals from randomization. The data appears to be presented in a format that tracks the cumulative incidence rates for both Rivaroxaban and Placebo over a span of days post-randomization. This information could be used to evaluate the effectiveness and safety profile of Rivaroxaban in comparison to a placebo in the context of the clinical trial.*

FDA Label Image

Figure-11 (Figure 11)

This appears to be a description of a clinical trial evaluating the effectiveness of rivaroxaban versus a placebo in a treatment group. The hazard ratio was compared at 0.85 with a 95% confidence interval of 0.76 to 0.95. The text also mentions the number of subjects at risk over different days from randomization. The trial seems to involve a significant number of subjects over several days of observation.*

FDA Label Image

Figure-12 (Figure 12)

FDA Label Image

Container-label-10mg-30s (Riva 10mg 30s)

FDA Label Image

Container-label-2.5mg-60s (Riva 2 5 60s)

This text provides information about Rivaroxaban Tablets USP containing 2.5 mg of rivaroxaban. It includes storage instructions, dosage details, manufacturing information, and important details like NDC and lot number. The text also emphasizes keeping the medication out of reach of children. Additionally, it mentions dispensing a Medication Guide to each patient.*

FDA Label Image

Rivaroxaban Carton 2 (Rivaroxaban Carton 2)

This is a prescription medication named Rivaroxaban Tablets USP containing 20 mg of rivaroxaban per tablet. It is intended for hospital use only and should be dispensed with an accompanying Medication Guide for each patient. The package includes 100 tablets in 10 blister strips. The usual dosage should be kept out of reach of children and stored at room temperature between 20°C to 25°C (68°F to 77°F). More information can be found in the package insert. The medication is manufactured by Indoco Remedies Ltd in India.*

FDA Label Image

Rivaroxaban Container 1 (Rivaroxaban Container 1)

This text provides important information about the usual dosage and storage instructions for the medication Rivaroxaban Tablets USP. It suggests storing the tablets at room temperature and dispensing the accompanying Medication Guide to each patient. Each tablet contains 15 mg of rivaroxaban. The manufacturer is Indoco Remedies Ltd. located in Verna Industrial Area, Goa, India.*

FDA Label Image

Rivaroxaban Container 3 (Rivaroxaban Container 3)

The text provides information about the usual dosage and storage conditions for a medication called Rivaroxaban Tablets USP. It includes details such as the temperature for storage, keeping the medication out of reach of children, manufacturer's information, code number, and the content of each tablet. It also mentions the need to dispense the accompanying Medication Guide to each patient.*

FDA Label Image

Rivaroxaban Starter Pack (Rivaroxaban Starter Pack)

This text provides information on Rivaroxaban Tablets USP for the treatment of deep vein thrombosis and pulmonary embolism. It includes details on dosage instructions, how to take the medication, and a reminder to consult with a doctor before making any changes to the prescribed dosage. The text also mentions the importance of following the provided Medication Guide and Full Prescribing Information. It highlights the recommended dosage of 15 mg tablet twice daily for the first 21 days, followed by a dosage of 20 mg tablet once daily for the remaining days.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.